A five-miRNA signature with prognostic and predictive value for *MGMT* promoter-methylated glioblastoma patients

Supplementary Material




Figure S1. Comparison of the expression levels of five miRNAs comprising the miRNA signature between normal brain tissue and GBM specimens with MGMT promoter methylation. Bars indicate standard deviation.




Figure S2. Prognostic value of the five-miRNA signature for PFS using independent set.




Figure S3. Lack of prognostic value for the five-miRNA signature in GBM patients without *MGMT* promoter methylation using the cutoff value of 0.0178 (A) or the median risk value (B).




Figure S4. Comparison of the five-miRNA signature and its constituent miRNAs between cases with long and short survival time using a combined set. *P < 0.05, **P < 0.01, ***P < 0.001.




Figure S5. Prognosis of unmethylated GBM samples and high- and low-risk GBM patients with *MGMT* promoter methylation using an independent set. *P < 0.05, **P < 0.01, ***P < 0.001.




Figure S6. Comparison of the five-miRNA signature and its constituent miRNAs between chemotherapy responders and non-responders. *P < 0.05, **P < 0.01, ***P < 0.001.




Figure S7. Sensitivity and specificity of the risk model for predicting 1-year survival using the independent set.

Table S1. Univariate Cox regression of miRNAs for survival in training set.

Table 51. Curvariate Cox regression of mile (745 for survivar in training set.				
P-value	HR	95%CI		
0.0112	1.6024	1.1129-2.3072		
0.0132	0.5809	0.3780-0.8925		
0.0202	0.6175	0.4112-0.9274		
0.0218	1.6954	1.0797-2.6623		
0.0456	1.3948	1.0066-1.9328		
	P-value 0.0112 0.0132 0.0202 0.0218	P-value HR 0.0112 1.6024 0.0132 0.5809 0.0202 0.6175 0.0218 1.6954		

Table S2. Cox hazard regression analysis of clinicopathologic factors and the five-miRNA signature for survival in the independent set

Variable	Univari	Univariate Cox		Multivariate Cox	
	P-value	HR	P-value	HR	
Age					
(Per 20 years)	0.3845	1.4990			
Gender					
(Female vs. Male)	0.5433	0.7195			
KPS					
(≥80 vs. <80)	0.4431	0.5296			
IDH1 mutation					
(Mutation vs. Wild type)	0.0469	0.1137	0.0305	0.0753	
Radiotherapy					
(Treated vs. Untreated)	0.0530	0.2504			
Chemotherapy					
(Treated vs. Untreated)	0.0937	0.3798			
Five-miRNA signature					
(High vs. Low risk)	0.0082	4.5896	0.0090	6.4662	